NewswireToday - /newswire/ -
Moscow, Russia, 2007/06/04 - According to Synergy Research Group the growth in the number of clinical trials approved by the Russian Federal Agency for Health Care and Social Development (Roszdravnadzor) made up to nearly 40% in the 1st Quarter of 2007 - synergy.dslx.ru.
On June 03, Synergy Research Group, a Russia-based CRO, presented the current issue of its Orange Paper, a regular analytical report on the market of clinical trials in Russia. The formation of a civilized market of clinical trials in Russia and improvement of the research attractiveness of Russia for foreign sponsors as well as exoneration of clinical trials in the eyes of Russian public are the key strategic objectives of Synergy Research Group.
According to the report, the growth in the number of clinical trials approved by the Russian Federal Agency for Health Care and Social Development (Roszdravnadzor) made up to nearly 40% in the 1st Quarter of 2007 as compared to the same quarter of the previous year. At the same time, the share of clinical studies initiated by Russian manufacturers has increased.
The report comprises four tables and seven figures reflecting different aspects of the clinical trials market in Russia: balance between different phases and types of clinical trials, shares of foreign and Russian sponsors, ratings of the leading Russian and foreign pharmaceutical manufacturers, analysis of the leader’s portfolio and many other facts of interest.
The first issue of the Orange Book featuring the general picture of the Russian clinical trials market as well as analysis of the studies conducted in Russia in 2006 was perceived with keen interest both in Russia and abroad. Experts from foreign pharmaceutical companies, international contract research organizations and foreign printed and online editions dealing with clinical studies gave high grades to the first issue of the Orange Paper, and two of them applied to Synergy Research Group for original articles on individual aspects of the Russian clinical trials market.
The Orange Paper will be published in Russia in an electronic format on the Synergy Research Group’s official Web page. New issues will also be published on the major pharmaceutical and biotechnology information portals. The English version will be distributed abroad on a subscription basis and published on popular sites covering clinical trials.
Hard copies will be distributed at Russian and international exhibitions and conferences devoted to clinical trials including the Clinical Studies of Drugs, the 6th International Conference, which will take place in Moscow on October 12, 2007, and Partnership in Clinical Trials 2007 international conference scheduled for November 5-8, 2007 in Amsterdam.
Synergy Research Group (SynRG™) is a Russian contract research organization, which has been successfully operating all over Russia and the CIS member-states since 2002. SynRG™ (synrg-pharm.com) offers a broad range of services for conducting clinical trials for Russian and foreign pharmaceutical and biotechnological companies – from registration of the studies in regulatory authorities to pharmaco-economic surveys. The company has its own clinical warehouse in Moscow, with the total area of 180 square meters. Today, Synergy Research Group is represented in Moscow, Saint-Petersburg, Novosibirsk, Yekaterinburg and Almaty. The company’s headquarters are in Moscow.